Clinical Evaluation of Approved Contact Lenses

Not Applicable

Completed

Conditions: Visual Acuity

Interventions: Device: Test Contact Lens
Device: Control Contact Lens

Registration Number: NCT02699593

Lead Sponsor: Johnson & Johnson Vision Care, Inc.

Brief Summary: This is a 4-week, randomized, double-masked study where subjects will wear bilaterally test and control lenses in random succession. The objective is to evaluate materials from different suppliers.

Detailed Description: Not available

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 142

Inclusion Criteria

The subject must read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form.
The subject must appear able and willing to adhere to the instructions set forth in this clinical protocol.
The subject must be at least 18 and not more than 70 years of age (including 70).
The subject's refractive cylinder must be < 0.75 Diopters (D) in each eye.
The subject must have best corrected visual acuity of 20/25 or better in each eye.
The subject must be a habitual and adapted wearer of ACUVUE® OASYS® brand contact lens in both eyes (at least 1 month of daily wear).
The subject must have normal eyes (i.e., no ocular medications or infections of any type).
The subject's required spherical contact lens prescription must be in the range of -1.00 D to -6.00 D in each eye.

Exclusion Criteria

Currently pregnant or lactating (subjects who become pregnant during the study will be discontinued).
Any ocular or systemic allergies or diseases that may interfere with contact lens wear.
Any systemic disease, autoimmune disease, or use of medication that may interfere with contact lens wear.
Entropion, ectropion, extrusions, chalazia, recurrent styes, glaucoma, history of recurrent corneal erosions, aphakia.
Any previous, or planned, ocular or interocular surgery (e.g., radial keratotomy, photorefractive keratectomy (PRK), laser-assisted in situ keratomileusis (LASIK), etc.)
Any grade 3 or greater slit lamp findings (e.g., edema, corneal neovascularization, corneal staining, tarsal abnormalities, conjunctival injection) on the FDA classification scale, any previous history or signs of a contact lens-related corneal inflammatory event (e.g., past peripheral ulcer or round peripheral scar), or any other ocular abnormality that may contraindicate contact lens wear.
Any known hypersensitivity or allergic reaction to OPTI-FREE® PureMoist® Contact Lens Solution.
Any ocular infection.
Any corneal distortion resulting from previous hard or rigid gas permeable contact lens wear.
Monovision or multi-focal contact lens correction.
Participation in any contact lens or lens care product clinical trial within 14 days prior to study enrollment.
History of binocular vision abnormality or strabismus.
Any infectious disease (e.g., hepatitis, tuberculosis) or a contagious immunosuppressive disease (e.g., HIV, by self-report).
Suspicion of or recent history of alcohol or substance abuse.
History of serious mental illness.
History of seizures.
Employee of investigational clinic (e.g., Investigator, Coordinator, Technician)

Study & Design

Study Type: INTERVENTIONAL

Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Test / Control Sequence	Control Contact Lens	Subjects will be dispensed the Test Contact Lens to wear for two weeks, to be worn in a daily wear modality, attending a follow-up visit in 12-17 days. At the follow-up visit, subjects will be dispensed the Control Contact Lens to wear for two weeks, to be worn in a daily wear modality.
Control / Test Sequence	Control Contact Lens	Subjects will be dispensed the Control Contact Lens to wear for two weeks, to be worn in a daily wear modality, attending a follow-up visit in 12-17 days. At the follow-up visit, subjects will be dispensed the Test Contact Lens to wear for two weeks, to be worn in a daily wear modality.
Test / Control Sequence	Test Contact Lens	Subjects will be dispensed the Test Contact Lens to wear for two weeks, to be worn in a daily wear modality, attending a follow-up visit in 12-17 days. At the follow-up visit, subjects will be dispensed the Control Contact Lens to wear for two weeks, to be worn in a daily wear modality.
Control / Test Sequence	Test Contact Lens	Subjects will be dispensed the Control Contact Lens to wear for two weeks, to be worn in a daily wear modality, attending a follow-up visit in 12-17 days. At the follow-up visit, subjects will be dispensed the Test Contact Lens to wear for two weeks, to be worn in a daily wear modality.

Primary Outcome Measures

Name	Time	Method
Visual Acuity (LogMAR)	2-week Follow-up	Distance Visual Acuity (LogMAR) was assessed using an ETDRS chart at the 2-week follow-up for each subject and eye for 2 conditions, Bright low contrast and Dim high contrast. The average visual acuity (LogMAR) for each condition and lens was reported.
Contact Lens Wearing Time	2-week follow-up	Contact lens wearing time was collected for each subject at the 2-week follow-up evaluation. The average contact lens wearing time in hours was reported for each lens.

Secondary Outcome Measures

Name	Time	Method

Trial Locations

Locations (7): University of Alabama at Birmingham
🇺🇸
Birmingham, Alabama, United States
Eye Elements Eyecare
🇺🇸
Jacksonville, Florida, United States
Golden Vision
🇺🇸
Sarasota, Florida, United States
Advantage Eyecare Associates, LLC
🇺🇸
Neodesha, Kansas, United States
Professional Vision Care
🇺🇸
Westerville, Ohio, United States
Advanced Eyecare, PC
🇺🇸
Raytown, Missouri, United States
Timothy R. Poling, OD
🇺🇸
Roanoke, Virginia, United States